美诺华：全资子公司获厄贝沙坦氢氯噻嗪片药品注册证书

Core Viewpoint - Meheco's subsidiary, Meheco Tiankang, has received approval from the National Medical Products Administration for the registration of Eprosartan Hydrochlorothiazide Tablets, which are used to treat primary hypertension [1] Company Summary - The approved drug is a combination of angiotensin II receptor antagonist Eprosartan and thiazide diuretic Hydrochlorothiazide [1] - Meheco Tiankang has invested 5.8747 million yuan in the research and development of this drug [1] Market Summary - The global sales forecast for Eprosartan Hydrochlorothiazide Tablets in 2024 is projected to be 817 million USD, with sales in China expected to reach 184 million USD [1]